Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have symptoms suggestive of ACS that lasted at least 10 minutes at rest occurring within 7 days of randomization~* Have a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial infarction/unstable angina (ie, chest pain or discomfort) (ST elevation is an abnormal finding from an ECG test) with at least 1 protocol-defined high risk feature~Exclusion Criteria:~* Active bleeding or high risk of bleeding or intracranial hemorrhage (bleeding within the skull enclosing the brain)~* Need for continued anticoagulant therapy~* Significantly impaired renal (kidney) or hepatic (liver) function~* Severe concomitant diseases such as cardiogenic shock (heart damage that results in insufficient blood supply to other parts or organs of the body), refractory ventricular arrhythmias (irregular contractions of the heart unresponsive to treatment), or any severe condition that would limit life expectancy of the patient to less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
- 002 (Type: EXPERIMENTAL): Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
- 003 (Type: PLACEBO_COMPARATOR): Placebo 1 placebo tablet twice daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).